Lindbrook Capital’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Lindbrook Capital’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-80	Closed	-$6K	–	3016
2022 Q2	$6K	Sell	80 -215	-73%	-$9.55K	﹤0.01%	1515
2022 Q1	$8K	Sell	295 -730	-71%	-$24.5K	﹤0.01%	1422
2021 Q4	$49K	Buy	+1,025	New	+$45.8K	0.01%	729
2021 Q2	–	Sell	-22	Closed	-$2K	–	2028
2021 Q1	$2K	Buy	+22	New	+$2.62K	﹤0.01%	1644
2020 Q1	–	Sell	-32	Closed	-$2K	–	1903
2019 Q4	$2K	Buy	+32	New	+$1.52K	﹤0.01%	1337

Lindbrook Capital's TPTX Position: Q3 2022 in Review

Lindbrook Capital sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 80 shares — an estimated $6K sold.

Lindbrook Capital first reported a position in TPTX in Q4 2019 and held it in 5 quarters. The position peaked at $49K in Q4 2021. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Lindbrook Capital reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Lindbrook Capital sold 80 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $6K.
Lindbrook Capital first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q4 2019 and held it in 5 quarters.
Lindbrook Capital's Turning Point Therapeutics, Inc. Common Stock position peaked at $49K in Q4 2021.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Lindbrook Capital's 13F filing for Q3 2022, filed 10 Nov 2022.